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Abstract
Objective: Using potential viruses to destroy cancer cells has a long history, but recent advances in molecular biology raised hopes
for successful use of these viruses again.
Methods: Octreotate sequence was inserted into the neutralization region (R1& R2) in vp2 protein of capsid segment in 10 seg-
mented genome of BTV in 304 - 368 position. T7 BTV RNA transcripts were extracted. Cancerous cultured cells were transfected with
wild and modified BTV to recover BTV with cDNA-derived genome segments.
Results: The results of all the performed experiments revealed that treatment of AGS cell lines with VP2 modified BTV16, which
targeted cell surface of cancerous cells, significantly increased apoptosis in cancer infected cells.
Conclusions: Modified VP2 BTV16 may be used as a potential virulytic oncotherapy agent in AGS cells.
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1. Background
Ability of viruses in delaying growth of human cancer-
ous cells has a long history and dates back to early 19th cen-
tury (1). In the late 19th century and for the first time, it was
suggested that reovirus in in vitro conditions could selec-
tively destroy selected human cancerous cells (2). This was
a novel discovery and raised hope that viruses (3) with on-
colytic potentials could be used as a killing machine to de-
stroy human cancerous cells (4, 5). Previous studies sug-
gested 6 major viral families: herpesviruses, flaviviruses,
papillomaviruses, reovirus type 3, hepadnaviruses, and
retroviruses with potential virulytic oncotherapy ability
(6-10), all of which, except reovirus, are human cancer
viruses.
There are not any reports on pathogenicity of blue-
tongue viruses to humans; moreover, it has been reported
that bluetongue viruses are merely pathogenic to domes-
tic cattle and wild ruminants (11). Thus, it is not surpris-
ing that there is not any pre-existing antibodies to BTVs in
humans (12). Infection of human normal cells such as pri-
mary murine embryos fibroblast (MEF), the primary hu-
man embryo lung fibroblast (HEL), and Madin-Darby ca-
nine kidney (MDCK) with BTVs were not successful (11-13).
Octreotate is an octapeptide that pharmacologically
looks like somatostatin (14, 15). Somatostatin and octreo-
tate are potentially active against several studied cancers
including colorectal carcinoma due to their antiprolifera-
tive and apoptosis-inducing activity. When octreotate be-
comes radiolabeled, it can be used well for imaging of dif-
ferent types of cancers including breast, endocrine, neu-
roendocrine, small-cell lung, and prostate. It has also been
used for targeted radiotherapy (16).
DeMaula et al. found that neutralization region (R1
& R2) in vp2 protein of capsid segment in 10 segmented
genome of BTV is 304 - 368. Thus, we proposed to place oc-
treotate in 321 - 346 position (17).
2. Objectives
The present study aimed at using BTV virus to geneti-
cally modify its spike through changing its capsid protein
antigenic epitope to target cancerous cell lines and check
apoptosis effect in infected host cells.
3. Methods
HeLa (human cervical epithelial carcinoma) cells were
maintained in Dulbecco’s modified Eagle’s medium, con-
taining 10% fetal calf serum (FCS), 100 U of penicillin/mL,
and 100 µg of streptomycin /mL and cells were incubated
at 37°C.
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Neutralization region (R1 & R2) in vp2 protein of capsid
segment in 10 segmented genome of BTV is 304 - 368 posi-
tion. Thus, we proposed to place octreotate in 321 - 346 posi-
tion in this segment. Therefore, in segment 2 gene of strain
of bluetongue virus 9 (accession number: JN2559639), with
a 2921 bp length, octreotate sequence was inserted in 1711
to 1734 bp position; and immediately before viral vp2 se-
quence a T7 promoter, and immediately after that a BsaI re-
striction site were inserted, and the whole sequence (2957
bp) was cloned into pUC57 (Cinna Gen, Tehran, Iran).
Competent Stella cells were transfected with pUC-
30434-Naserpour Plasmid and incubated over night at 37
degree centigrade with 200 rpm shaking. Cells were har-
vested by centrifuging, and after lysis, plasmids were ex-
tracted with plasmid extraction kit according to its man-
ual (Qiagen, Tehran, Iran). Extracted and purified plas-
mid was cut with BsaI restriction enzyme at 37/4h and elec-
trophoresed in agarose gel 0.8%. The cut plasmids were ex-
tracted from gel by Qiagen gel extraction kit using its man-
ual (Qiagen) and were used as template DNA to make RNA
with mMESSAGE mMACHINE T7 Ultra kit (Ambion) using its
manual (18) (Figure 2).
Then, T7 BTV transcripts were extracted and RNA pellets
were washed twice in 70% (vol/vol) ethanol and dissolved
in sterile DPEC treated water. Purified BTV single-stranded
RNA (ssRNA) was analyzed by electrophoresis on 1% dena-
turing agarose using standard techniques (29) (Figure 3).
Purified BTV single-stranded RNA was stored at -80°C.
Cultured cells were transfected to recover BTV with
cDNA-derived genome segments. BTV mRNAs were mixed
with T7 BTV transcripts in Opti-MEM I in the presence of
0.1 U/µL RNasin Plus (Cinna Gen, Tehran, Iran). The RNA
mixture was incubated at 20°C for 30 minutes before be-
ing mixed with prepared liposome. Monolayers of HeLa
cells in 6 well plates were transfected with 1.5 µg of BTV
mRNA, which was mixed with 0.75 µg of T7 BTV transcript
using prepared liposome reagent according to the manu-
facturer’s instructions. Four hours after transfection, the
culture medium was replaced with a 6-mL overlay consist-
ing of minimal essential medium, 1.5% (wt/vol) agarose
type VII (Sigma) and 2% FBS. Assays were incubated at 35°C
in 5% CO2 for 72 to 96 hours to allow plaques to appear.
To prepare dsRNA from transfection-derived BTV
plaques, each plaque was picked into 500µL of Dulbecco’s
modified Eagle’s medium containing 5% FBS, and 200 µL
was used to infect 1.5 × 106 AGS cells. Infected cells were
incubated at 35°C in 5% CO2 incubator for 72 to 96 hours to
allow amplification of the BTV.
BTV serotype 16 (BTV-16), tittered by a plaque assay at 2.5
× 107 PFU/mL, was used for cell infection. First, cell mono-
layers were washed with FCS-free growth medium, and
then cell monolayers were incubated with viruses at the
required multiplicity of infection (MOI). Virus adsorption
was done for 2 hours, followed by incubation in growth
medium supplemented with 5% FCS.
To detect chromosomal DNA fragmentation, approxi-
mately 2× 106 AGS cells were resuspended and lysed in ly-
sis solution, containing 0.5% Triton X-100, 5 mM Tris-HCl
(pH 7.4), and 5 mM EDTA, and maintained for 20 minutes
on ice. Nuclei were removed by centrifugation at 10,000
× g for 15 minutes. Supernatants were treated with 50
µg of RNase A/mL for 1 hour at 37°C, and DNAs were ex-
tracted by the standard phenol-chloroform extraction, and
precipitated pellets were dissolved in Tris-EDTA (pH 7.5).
DNAs with different size fragments were separated by elec-
trophoresis in 2% agarose gels.
4. Results and Discussion
Plasmid map of pUC57, inserted with segment 2 gene of
bluetongue virus 16, which was substituted with an octreo-
tate sequence in position 1711to 1734 bp, had a T7 promoter
immediately before and BsaI restriction site immediately
after vp2 gene (Figure 1).
This fragment had segment 2 gene of bluetongue virus
16 substituted with an octreotate sequence in position 1711
to 1734, a T7 promoter immediately before and BsaI restric-
tion site immediately after VP2 gene.
Results of treating plasmid pUC-30434-Naserpour with
BsaI or PacI restriction enzyme are presented in Figure 2.
Figure 3 illustrates that T7 BTV transcripts with 2921 bp
size were produced using mMESSAGE mMACHINE T7 Ultra
Kit.
AGS cells were treated with normal and modified
BTV16. Infection of AGS with modified BTV16, with an oc-
treotate part in their VP2 protein, led to apoptosis in this
cell (Figure 4).
Evaluation of apoptosis by Apoptotic DNA Ladder in
AGS treated with Normal BTV16 and VP2 modified BTV16
revealed that DNA laddering and fragmentation were ob-
served in AGS cells treated with VP2 modified BTV16 (Figure
5).
Virulytic oncotherapy has raised hope that viruses
(Kim et al. 2006) with oncolytic potentials can be used as a
killing machine to destroy human cancers cells (Liu, 2006;
Holtz, 2007). In this study, VP2 modified BTV16 were pre-
pared for this purpose, and the results of all the performed
confirming experiments revealed that treatment of AGS
cell lines with VP2 modified BTV16 which targeted cell sur-
face of cancerous cells, significantly increased apoptosis in
these cells. Thus, it is possible to use this virus as a potential
virulytic oncotherapy agent.
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Figure 1. pUC57 with 30434-Naserpour Fragment
Figure 2. pUC57-30434 Naserpour Treated with BsaI or PstI Restriction Enzyme
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Figure 3. T7 BTV Transcripts of Octreotate Inserted VP2 of BTV16
Figure 4. A: AGS Cells Treated with Normal BTV16. B: AGS Cells Treated with VP2 Modified BTV16
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